Moving away from the typical crypto posts today.
We are checking out MRK.
This stock has seen some hefty losses in the past few days, pushing the RSI into a oversold area
The increasing bear volume has not been supportive, and the price is breaking past the .382 fib level.
The stock is looking to find support, but the last few days have not...
Biogen has lost over 30% of its value this month. Looking at the monthly chart, we have concluded that this is a rare investment opportunity as the current price is just above its 1M Support Zone.
Historically we see that such an aggressive sell off recently took place in 2015 - 2016 and again the stock managed to recover almost reaching the 390 Resistance...
To General People
The same genes responsible for regrowing new limbs after amputation of a salamander exist in your body right now. It's turned off after a few days during fetal development and replaced with the scar gene, a possible vascular survival mechanism of mammalian evolution. Leonard Hayflick limit shows death is inevitable via cell division...
AMRS has been on a downward spiral for the last couple of years, but within recent time thcompany is pledging towards creating an effective approach towards future advancements. While also presenting at the paradigm capital biosynthesis conference on April 15th in Toronto. (Source Yahoo Finance)
Not investment advice. For personal and educational purposes only....
Slow down in China and Europe, Recession in Germany, Trade tension between US/China, Fed capitulation, Bear market rally exceeding 40% from lows, etc., etc., etc... all seem to point towards another leg down, possibly beyond previous lows. Over excitement by the bulls after yesterday's rally adds to my conviction that we may be heading lower, and possibly much...
Take position 223.05
Stoploss at after 222,
Take profit 228
if that breaks, switch to short and ride it to to 205.
But PE is really low for a bio stock,fundamentally, it's good value.
If we get a rally again in the market and sector(LABU) continue to push. this will probably go sideways.
Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19,
interim six-month data expected in 4Q19
Collaboration with CureCN projected to dose first patient with combination of ImmTOR + AAV
gene therapy candidate in 2H19
Company raises $33M in gross offering proceeds and $31.3M in net proceeds in 1Q19, cash
runway into 1Q20...
lot of lines and PTs can elevate fast if this breaks out on volume inflation in April
Notice the 1M candle is Red 9 for March. Ideal play here is an entry under $2.00 (on support retest)
if we change cycle from accumulation to Bull Cycle, look for late 2019 take profit area (Sept-Dec)
Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin.
- Double bottom which is normally an indicator for a reversal.
- higher high and higher low
- Oversold Stoch RSI (4hr)
Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration.
Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...
As mentioned in an earlier Idea ( ), the Q4 report represented a substantial risk for a downwards reaction after a recent surge in the share price.
At the new price level around NOK 41 the stock is much more attractively priced, and this could be the time...
Photocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks.
As mentioned in an earlier TradingView analysis (), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK...
A lot of volume came in on Friday closing as a doji at major resistance. Shorts are most likely hopping on board here. Going down to the 4H you can see there is an ascending triangle.
My plan is to enter above February 7th's high with March $85 calls. Should be a strong momentum move to the upside if volume moves in on a breakout of the downtrend line.